03-07-2020 | Artikelen | Uitgave 3/2020

De relatie tussen gehechtheid en depressie bij kinderen en adolescenten: een multilevel meta-analyse
- Tijdschrift:
- Kind en adolescent > Uitgave 3/2020
Inleiding
Veilige en onveilige gehechtheidsrelaties
Depressie bij kinderen en adolescenten
De relatie tussen gehechtheid en depressie
De huidige studie
Methode
Inclusiecriteria
Selectie van studies en publicatiebias beperken
Het coderen van de studies
Berekeningen en analyses
Resultaten
s
|
k
|
β
0
|
r
|
t
0
|
||||
---|---|---|---|---|---|---|---|---|
Globale associatie gehechtheid en depressie
|
123
|
643
|
0,324
|
0,313
|
22,177
|
|||
Moderatoren
|
s
|
k
|
β
0
|
r
|
t
0
|
β
1
|
t
1
|
F
(df1, df2)
|
Studiekenmerken
|
||||||||
Publicatiejaar (cont.)
|
123
|
643
|
0,324
|
0,313
|
22,096
***
|
−0,001
|
−0,661
|
F (1,641) = 0,437
|
Impactfactor (cont.)
|
105
|
541
|
0,327
|
0,316
|
21,178
***
|
−0,024
|
−2,331
*
|
F (1,539) = 5,435
*
|
Publicatiestatus
|
123
|
643
|
F (1,641) = 0,879
|
|||||
– Gepubliceerd (RC)
|
106
|
541
|
0,325
|
0,314
|
20,425
***
|
|||
– Niet gepubliceerd
|
17
|
102
|
0,319
|
0,309
|
8,405
***
|
−0,006
|
−0,152
|
|
Land
|
123
|
613
|
F (1,611) = 12,028
***
|
|||||
– Westers (RC)
|
112
|
554
|
0,316
|
0,306
|
21,419
***
|
|||
– Niet-westers
|
13
|
59
|
0,393
|
0,374
|
15,932
***
|
0,077
|
3,468
***
|
|
Studiedesign
|
123
|
643
|
F (1,641) = 39,184
***
|
|||||
– Crosssectioneel (RC)
|
97
|
462
|
0,361
|
0,346
|
23,661
***
|
|||
– Longitudinaal
|
32
|
181
|
0,203
|
0,200
|
8,502
***
|
−0,158
|
−6,260
***
|
|
Tijd tussen gehechtheids- en depressiemaat (cont.)
|
123
|
637
|
0,330
|
0,319
|
24,127
***
|
−0,002
|
−5,417
***
|
F (1,635) = 29,344
***
|
Steekproefkenmerken
|
||||||||
Gemiddelde leeftijd gehechtheidsmaat (cont.)
|
112
|
609
|
0,328
|
0,317
|
22,069
***
|
0,010
|
2,835
**
|
F (1,607) = 8,036
**
|
Gemiddelde leeftijd depressiemaat (cont.)
|
112
|
609
|
0,327
|
0,316
|
21,276
***
|
−0,003
|
−0,741
|
F (1,607) = 0,549
|
Geslacht
|
120
|
627
|
F (2,624) = 8,036
**
|
|||||
– Alleen jongens (RC)
|
8
|
33
|
0,341
|
0,328
|
9,914
***
|
|||
– Alleen meisjes
|
21
|
79
|
0,403
|
0,383
|
14,040
***
|
0,063
|
2,086
*
|
|
– Gemengd
|
101
|
627
|
0,314
|
0,304
|
20,948
|
−0,027
|
−0,777
|
|
Gezinsrisicostatus
|
123
|
643
|
F (2,640) = 0,467
|
|||||
– Geen risico (RC)
|
72
|
511
|
0,330
|
0,319
|
19,656
***
|
|||
– Risicosteekproef
|
19
|
87
|
0,318
|
0,308
|
8,151
***
|
−0,013
|
−0,301
|
|
– Gemengd
|
12
|
45
|
0,283
|
0,276
|
6,020
***
|
−0,047
|
−0,950
|
|
Proportie Europees (cont.)
|
68
|
322
|
0,301
|
0,292
|
15,420
***
|
−0,058
|
−1,034
|
F (1,320) = 1,070
|
Gehechtheidskenmerken
|
||||||||
Gehechtheidsfiguur
|
123
|
643
|
F (3,639) = 0,278
|
|||||
– Ouders (RC)
|
53
|
207
|
0,314
|
0,304
|
16,302
***
|
|||
– Moeder
|
62
|
234
|
0,332
|
0,320
|
17,784
***
|
0,018
|
0,822
|
|
– Vader
|
31
|
132
|
0,326
|
0,315
|
15,881
***
|
0,012
|
0,519
|
|
– Algemene representaties
|
14
|
70
|
0,330
|
0,319
|
9,207
***
|
0,016
|
0,419
|
|
Gehechtheidsstijl
|
82
|
521
|
F (4,516) = 5,067
***
|
|||||
– Veilig (RC)
|
42
|
264
|
0,307
|
0,298
|
13,575
***
|
|||
– Vermijdend
|
29
|
57
|
0,273
|
0,266
|
9,680
***
|
−0,033
|
−1,173
|
|
– Ambivalent
|
32
|
55
|
0,320
|
0,310
|
11,245
***
|
0,013
|
0,442
|
|
– Gedesorganiseerd
|
12
|
27
|
0,379
|
0,362
|
8,959
***
|
0,073
|
1,718
+
|
|
– Onveilig
|
35
|
118
|
0,353
|
0,339
|
15,013
***
|
0,046
|
3,537
***
|
|
Gehechtheidsmaat
|
123
|
643
|
F (1,641) = 13,358
***
|
|||||
– Continu (RC)
|
112
|
552
|
0,341
|
0,328
|
23,758
***
|
|||
– Categorisch
|
24
|
91
|
0,229
|
0,225
|
7,894
***
|
−0,112
|
3,655
***
|
|
Gehechtheidsinstrument
|
123
|
643
|
F (2,640) = 20,381
***
|
|||||
– Vragenlijst (RC)
|
100
|
518
|
0,358
|
0,343
|
25,652
***
|
|||
– Interview
|
11
|
78
|
0,156
|
0,155
|
3,787
***
|
−0,203
|
−4,748
***
|
|
– Observatie/experiment
|
14
|
47
|
0,162
|
0,161
|
4,030
***
|
−0,197
|
−4,657
***
|
|
Informant gehechtheid
|
123
|
642
|
F (1,640) = 12,687
***
|
|||||
– Kind (RC)
|
112
|
605
|
0,338
|
0,326
|
23,484
***
|
|||
– Observator
|
12
|
37
|
0,165
|
0,164
|
3,509
***
|
−0,173
|
−3,562
***
|
|
Depressiekenmerken
|
||||||||
Depressiemaat
|
123
|
643
|
F (1,641) = 0,039
|
|||||
– Symptomen (RC)
|
116
|
608
|
0,325
|
0,314
|
21,618
***
|
|||
– Klinische diagnose
|
11
|
35
|
0,315
|
0,305
|
6,900
***
|
−0,009
|
−0,196
|
|
Instrument depressie
|
122
|
639
|
F (1,637) = 0,479
|
|||||
– Vragenlijst (RC)
|
117
|
600
|
0,326
|
0,315
|
21,516
***
|
|||
– Interview
|
14
|
39
|
0,296
|
0,288
|
6,977
|
−0,030
|
−0,692
|
|
Informant depressie
|
121
|
627
|
F (1,625) = 2,442
|
|||||
– Kind (RC)
|
120
|
597
|
0,327
|
0,316
|
22,375
***
|
|||
– Ouder
|
5
|
30
|
0,273
|
0,266
|
7,458
***
|
−0,054
|
−1,563
|
Globale relatie tussen gehechtheid en depressie
Moderatoren van de relatie tussen gehechtheid en depressie
Studiekenmerken
Steekproefkenmerken
Gehechtheidskenmerken
Depressiekenmerken
Multivariaat model
s
|
k
|
β
|
t
|
F (df1, df2)
|
σ
2 level 3
|
σ
2 level 2
|
|
---|---|---|---|---|---|---|---|
Multivariaat model
|
66
|
404
|
F (9,394) = 9,390
***
|
0,018
|
0,006
|
||
– Intercept
|
0,242
|
2,984
**
|
|||||
– Impactfactor
|
0,009
|
0,725
|
|||||
– Niet-westerse landen
|
0,077
|
3,910
***
|
|||||
– Longitudinaal design
|
−0,137
|
−4,396
***
|
|||||
– Leeftijd tijdens gehechtheidsmaat
|
−0,008
|
−1,315
|
|||||
– Meisjessteekproef
|
0,113
|
3,668
***
|
|||||
– Onveilige gehechtheid
|
0,047
|
3,332
***
|
|||||
– Categorische gehechtheidsmaat
|
0,005
|
0,126
|
|||||
– Gehechtheidsvragenlijst
|
0,197
|
3,902
***
|
|||||
– Kindinformant gehechtheid
|
0,006
|
0,082
|
Discussie
Globale relatie tussen gehechtheid en depressie
Moderatoren van de associatie tussen gehechtheid en depressie
Beperkingen
Implicaties voor onderzoek en klinische praktijk
Conclusie
Bijlage A
Bijlage B
Geïncludeerde studies
Bijlage C
Auteurs
|
Jaar
|
N
|
Studiedesign
|
Leeftijd Geh
|
Leeftijd Dep
|
Geh maat
|
Dep maat
|
---|---|---|---|---|---|---|---|
1. Abela et al.
|
2005
|
140
|
Cross
|
9,80
|
9,80
|
IPPA
|
CDI, K‑SADS, BDI
|
2. Agerup et al.
|
2015
|
159
|
Long
|
15,00
|
20,00
|
IPPA
|
K‑SADS-PL
|
3. Aifuwa
|
2016
|
75
|
Cross
|
n/a
|
n/a
|
PAQ
|
CES‑D
|
4. Allen et al.
|
2007
|
167
|
Long
|
13,36
|
13,36
|
AAI Q‑set
|
CDI
|
14,29
|
14,29
|
||||||
15,22
|
15,22
|
||||||
5. Armsden et al.
|
1990
|
55
|
Cross
|
13,53
|
13,53
|
IPPA
|
K‑SADS, CDI
|
6. Armsden et al.
|
1987
|
86
|
Cross
|
18,60
|
18,60
|
IPPA
|
ASI
|
7. Bamaca-Colbert
|
2012
|
170
|
Cross
|
12,26
|
12,26
|
IPPA
|
CES‑D
|
15,20
|
15,20
|
||||||
8. Bauman et al.
|
2006
|
50
|
Cross
|
12,40
|
12,40
|
IPPA
|
CDI
|
13,00
|
13,00
|
||||||
9. Bennett et al.
|
2005
|
80
|
Long
|
1,13
|
7,50
|
SSP
|
BASC
|
10. Bogard
|
2005
|
201
|
Cross
|
12,60
|
12,60
|
IPPA
|
CDI
|
11. Borelli et al.
|
2010
|
97
|
Long
|
10,10
|
10,10
|
CAI
|
HIF, PANAS‑C
|
12. Borelli et al.
|
2017
|
106
|
Long
|
10,30
|
10,30
|
SS
|
CDI
|
13. Bosmans et al.
|
2016
|
60
|
Cross
|
10,45
|
10,45
|
ECR-RC
|
CES‑D
|
14. Bosquet
|
2006
|
155
|
Long
|
1,00
|
17,50
|
SSP
|
K‑SADS
|
15. Branje et al.
|
2010
|
1313
|
Long
|
n/a
|
n/a
|
IPPA
|
CDI
|
16. Brenning et al.
|
2011
|
303
|
Cross
|
12,00
|
12,00
|
ECR-RC
|
CDI
|
17. Brenning et al.
|
2012
|
238
|
Cross
|
14,46
|
14,46
|
ECR-RC
|
CDI
|
18. Brenning et al.
|
2012
|
339
|
Cross
|
12,60
|
12,60
|
ECR-RC
|
CDI
|
19. Brenning et al.
|
2013
|
289
|
Long
|
12,00
|
12,00
|
ECR-RC
|
CDI
|
13,00
|
13,00
|
||||||
14,00
|
14,00
|
||||||
15,00
|
15,00
|
||||||
20. Brodie
|
2004
|
169
|
Cross
|
n/a
|
n/a
|
IPPA
|
BDI
|
21. Buist et al.
|
2004
|
285
|
Long
|
13,50
|
13,50
|
IPPA
|
NPBL
|
14,50
|
14,50
|
||||||
15,50
|
15,50
|
||||||
22. Bureau et al.
|
2009
|
47
|
Long
|
1,50
|
8,00
|
SSP
|
DDPCA, CES‑D
|
19,00
|
|||||||
23. Burge et al.
|
1997
|
137
|
Long
|
18,17
|
18,17
|
IPPA
RAAS
|
SCID
|
24. Cawthorpe et al.
|
2004
|
73
|
Cross
|
15,50
|
15,50
|
AAQ
|
DISC‑R
|
25. Chaodiang
|
2008
|
950
|
Cross
|
17,00
|
17,00
|
IPPA
|
CES‑D
|
26. Chedebois et al.
|
2009
|
292
|
Cross
|
17,00
|
17,00
|
IPPA
|
CES‑D
|
27. Chesmore
|
2017
|
493
|
Cross
|
10,40
|
10,40
|
IPPA
|
TSCC
|
28. Cole-Detke et al.
|
1996
|
41
|
Cross
|
18,60
|
18,60
|
AAI
|
BDI
|
29. Constantine et al.
|
2006
|
283
|
Cross
|
16,57
|
16,57
|
IPPA
|
CDI
|
30. Cooper-Newark
|
2015
|
180
|
Cross
|
16,69
|
16,69
|
ECR-RC GSF
|
BDI
|
31. Cotterell
|
1992
|
29
|
Cross
|
15,90
|
15,90
|
IPPA
|
BDI
|
32. Crittenden et al.
|
2015
|
44
|
Beide
|
5,70
|
5,70
|
PAA
|
CDI
|
6,20
|
|||||||
33. Demidenko
|
2015
|
116
|
Cross
|
n/a
|
n/a
|
IPPA
|
Dossierinfo
|
34. De Minzi
|
2006
|
1019
|
Cross
|
10,06
|
10,06
|
KSS
|
DDPCA
|
35. Dhillon en Kanwar
|
2015
|
100
|
Cross
|
13,25
|
13,25
|
IPPA
|
CES‑D
|
13,94
|
13,94
|
||||||
36. Diamond et al.
|
2002
|
15
|
Long
|
14,90
|
14,90
|
IPPA
|
BDI
|
37. Djuardin et al.
|
2016
|
98
|
Beide
|
10,39
|
10,39
|
ECR-RC
|
CES‑D
|
11,98
|
11,98
|
||||||
38. Duchesne et al.
|
2014
|
416
|
Long
|
11,00
|
11,00
|
SS
|
CDI‑S
|
12,00
|
|||||||
13,00
|
|||||||
14,00
|
|||||||
15,00
|
|||||||
16,00
|
|||||||
39. Eberhart en Hammen
|
2006
|
97
|
Cross
|
17,92
|
17,92
|
IPPA
RAAS
|
BDI
|
40. Ehrlich et al.
|
2011
|
189
|
Cross
|
16,50
|
16,50
|
AAI
|
CDI, CES‑D
|
41. Engels et al.
|
2000
|
508
|
Cross
|
13,00
|
13,00
|
IPPA
|
DML
|
16,50
|
16,50
|
||||||
42. Essau
|
2004
|
600
|
Cross
|
14,30
|
14,30
|
IPPA
|
CIDI
|
43. Formoso et al.
|
2000
|
284
|
Cross
|
13,30
|
13,30
|
IPPA
|
CDI
|
44. Fox en Borelli
|
2015
|
107
|
Cross
|
9,74
|
9,74
|
CAI
|
CDI
|
45. Gatz
|
2000
|
162
|
Cross
|
n/a
|
n/a
|
PAS
|
BDI
|
46. Gaylord-Harden et al.
|
2009
|
392
|
Beide
|
12,03
|
12,03
|
IPPA
|
CDI
|
13,03
|
|||||||
47. Glazebrook et al.
|
2015
|
51
|
Cross
|
n/a
|
n/a
|
CAI
|
HADS
|
48. Goodman et al.
|
2012
|
36
|
Cross
|
7,97
|
7,97
|
ASCT, ADP
|
CDI, DICA
|
49. Graham et al.
|
2000
|
65
|
Cross
|
8,00
|
8,00
|
MC
|
DDPCA
|
50. Gullone et al.
|
2006
|
326
|
Cross
|
9,02
|
9,02
|
FDP
|
CDI
|
51. Halamova en Poplkova
|
2015
|
139
|
Cross
|
10,79
|
10,79
|
SS
|
CDI
|
52. Halamova en Poplkova
|
2015
|
151
|
Cross
|
11,20
|
11,20
|
SS
|
CDI
|
53. Henderson
|
2009
|
86
|
Cross
|
16,10
|
16,10
|
A‑RQ
|
HADS Depression
|
54. Hüsler et al.
|
2005
|
1028
|
Cross
|
n/a
|
n/a
|
IPPA
|
CES‑D
|
55. Irons en Gilbert
|
2005
|
140
|
Cross
|
14,63
|
14,63
|
RQ
|
CDI
|
56. Jinyao et al.
|
2012
|
662
|
Cross
|
20,11
|
20,11
|
ASQ
|
MASQ
|
57. Kamkar et al.
|
2012
|
140
|
Cross
|
12,65
|
12,65
|
ARSQ
|
CDI
|
58. Katz et al.
|
2009
|
163
|
Cross
|
n/a
|
n/a
|
AAS
|
CES‑D
|
59. Kenny et al.
|
1998
|
132
|
Beide
|
14,00
|
14,00
|
PAQ
|
CDI
|
15,00
|
15,00
|
||||||
60. Kenny et al.
|
2002
|
100
|
Cross
|
16,00
|
16,00
|
PAQ
|
CDI
|
61. Kerns et al.
|
2011
|
87
|
Cross
|
11,32
|
11,32
|
SST, SS
|
CDI
|
62. Kerr
|
2010
|
151
|
Beide
|
11,60
|
11,60
|
IPPA
|
BDI-II
|
12,60
|
|||||||
63. Kim et al.
|
2017
|
557
|
Cross
|
12,96
|
12,96
|
IPPA
|
CES‑D
|
64. Korbel
|
2009
|
100
|
Cross
|
13,46
|
13,46
|
ECR, SS
|
CDI
|
65. Kullik en Peterman
|
2013
|
248
|
Cross
|
14,41
|
14,41
|
IPPA
|
CES‑D
|
66. Laible et al.
|
2000
|
89
|
Cross
|
16,00
|
16,00
|
IPPA
|
CDI
|
67. Leas et al.
|
2000
|
108
|
Cross
|
18,90
|
18,90
|
IPPA
|
BDI
|
68. Lee et al.
|
2009
|
350
|
Long
|
14,50
|
14,50
|
ECR‑R
|
CDI
|
14,81
|
|||||||
69. Leenaars et al.
|
2008
|
2319
|
Cross
|
n/a
|
n/a
|
IPPA
|
CES‑D
|
70. Lecompte et al.
|
2014
|
58
|
Long
|
3,70
|
11,70
|
SSP
|
DIQ
|
71. Li et al.
|
2014
|
197
|
Cross
|
18,38
|
18,38
|
IPPA
|
BDI-II
|
72. Li et al.
|
2015
|
2632
|
Cross
|
13,84
|
13,84
|
IPPA‑R
|
CDI
|
13,90
|
13,90
|
||||||
73. Liebman
|
1997
|
125
|
Long
|
16,00
|
16,00
|
AAI Q set, IPPA
|
BDI, YSR, WAI
|
18,00
|
18,00
|
||||||
74. Liu
|
2006
|
1289
|
Cross
|
14,00
|
14,00
|
CPS
|
CDI
|
75. Marini et al.
|
2006
|
7290
|
Cross
|
15,58
|
15,58
|
IPPA
|
CES‑D
|
76. Marsh et al.
|
2003
|
123
|
Cross
|
15,90
|
15,90
|
AAI Q set
|
BDI
|
77. McCann et al.
|
2014
|
5371
|
Long
|
14,20
|
16,71
|
IPPA
|
CDI
|
78. McConnell
|
2008
|
27
|
Cross
|
17,10
|
17,10
|
AAQ, AUAQ
|
BDI
|
79. Milan et al.
|
2009
|
938
|
Long
|
3,00
|
11,00
|
SSP
|
CDI
|
80. Milne en Lancaster
|
2001
|
59
|
Cross
|
17,70
|
15,70
|
IPPA
|
DEQ‑A
|
81. Moss et al.
|
2006
|
72
|
Long
|
6,30
|
8,50
|
MC
|
Dominic Test
|
82. Moutisiana et al.
|
2014
|
54
|
Long
|
1,50
|
22,00
|
SSP
|
KSAD, SCID, CES‑D
|
83. Muris et al.
|
2001
|
155
|
Cross
|
12,90
|
12,90
|
IPPA
|
CDI
|
84. Nicholas
|
1997
|
166
|
Cross
|
15,95
|
15,95
|
IPPA
|
CES‑D
|
188
|
16,08
|
16,08
|
|||||
85. Noom et al.
|
2000
|
400
|
Cross
|
15,00
|
15,00
|
IPPA
|
DML
|
86. Omidvar et al.
|
2014
|
395
|
Cross
|
15,70
|
15,70
|
IPPA
|
BDI
|
87. O’Shea et al.
|
2013
|
61
|
Cross
|
15,19
|
15,19
|
ASQ
|
K‑SADS‑E
|
88. Pan
|
2016
|
1506
|
Cross
|
15,21
|
15,21
|
IPPA
|
CES‑D
|
89. Papafratzeskakou
|
2011
|
261
|
Cross
|
12,50
|
12,50
|
IPPA
|
CDI
|
90. Papini et al.
|
1991
|
231
|
Cross
|
12,80
|
12,80
|
IPPA
|
CDI
|
91. Papini et al.
|
1992
|
47
|
Long
|
12,60
|
12,60
|
IPPA
|
CDI
|
13,18
|
13,18
|
||||||
13,76
|
13,76
|
||||||
92. Pettineo
|
2011
|
177
|
Beide
|
14,00
|
14,00
|
IPPA
|
YSR
|
15,00
|
|||||||
93. Priddis et al.
|
2012
|
83
|
Long
|
5,00
|
12,00
|
SSP
|
CDI
|
94. Rawatlal et al.
|
2015
|
206
|
Cross
|
13,02
|
13,02
|
ECR
|
CDI
|
95. Rezvan et al.
|
2012
|
221
|
Cross
|
11,00
|
11,00
|
IPPA
|
DSRS
|
96. Roalson
|
2007
|
167
|
Cross
|
12,47
|
12,47
|
IPPA
|
CES-DC
|
97. Ridenour et al.
|
2006
|
310
|
Cross
|
11,02
|
11,02
|
PIML
|
RCDS
|
98. Roelofs et al.
|
2006
|
230
|
Cross
|
10,50
|
10,50
|
RQ
|
RCADS
|
99. Roelofs et al.
|
2011
|
222
|
Cross
|
14,70
|
14,70
|
IPPA
|
BDI
|
100. Ruijten et al.
|
2011
|
455
|
Cross
|
14,30
|
14,30
|
IPPA
|
BDI
|
101. Salzman
|
1996
|
21
|
Cross
|
n/a
|
n/a
|
AAI
|
CES‑D
Interview depressie
|
102. Schoenfelder et al.
|
2011
|
109
|
Long
|
17,30
|
11,30
|
IPPA
|
CBCL
YSR
|
11,30
|
|||||||
103. Shochet et al.
|
2008
|
152
|
Cross
|
15,20
|
15,20
|
PAQ
|
CDI
|
104. Silverman
|
2003
|
451
|
Cross
|
16,02
|
16,02
|
RSQ, RQ
|
BDI, CES‑D
|
105. Sim et al.
|
2011
|
130
|
Cross
|
12,58
|
12,58
|
Sim & Loh
|
AADS
|
15,50
|
15,50
|
||||||
106. Smojver Azic
|
2015
|
219
|
Cross
|
19,02
|
21,02
|
ECR
|
BDI-II
|
107. Speekenbrink et al.
|
2016
|
50
|
Cross
|
15,88
|
15,88
|
AAI
|
Diagnose door clinicus
|
108. Stebbins
|
2008
|
510
|
Cross
|
12,89
|
12,89
|
AAQ
|
CDI
|
13,68
|
13,68
|
||||||
14,60
|
14,60
|
||||||
109. Sund et al.
|
2002
|
1973
|
Long
|
13,70
|
13,70
|
IPPA
|
MFQ
|
110. Suzuki en Tomoda
|
2015
|
342
|
Cross
|
13,50
|
13,50
|
IWMQ
|
BDSSC
|
111. Szalai et al.
|
2017
|
5214
|
Cross
|
14,80
|
14,80
|
ECR-RC
|
CDI
|
112. Trapani
|
2007
|
55
|
Long
|
1,13
|
7,00
|
SSP
|
BPI
|
113. Van de Wallen et al.
|
2016
|
381
|
Cross
|
10,91
|
10,91
|
ECR-RC
|
CDI
|
11,25
|
11,25
|
||||||
114. Van Hoof et al.
|
2015
|
56
|
Cross
|
15,54
|
15,54
|
AAI
|
CDI, ADIS
|
115. Van Leeuwen
|
2010
|
292
|
Cross
|
17,10
|
17,10
|
IPPA
|
CES‑D
|
116. Vassallo et al.
|
2014
|
993
|
Long
|
13,50
|
19,50
|
IPPA
|
DASS21
|
117. Venta et al.
|
2014
|
114
|
Cross
|
14,68
|
14,68
|
SS
|
BDI, YSR
|
118. Venta et al.
|
2014
|
194
|
Cross
|
15,97
|
15,97
|
CAI
|
YSR, CBCL
|
119. Vivona
|
2000
|
77
|
Cross
|
19,98
|
19,98
|
IPPA
|
BDI
|
120. Wilkinson
|
2010
|
495
|
Cross
|
16,41
|
16,41
|
IPPA
|
Wilkinson Scale for Depression
|
121. Wong
|
2000
|
144
|
Cross
|
15,70
|
15,70
|
IPPA
|
CES‑D
|
122. Woodhouse et al.
|
2010
|
189
|
Cross
|
n/a
|
n/a
|
AAI
PSBS
|
CDI
|
123. Yeh et al.
|
2013
|
284
|
Cross
|
19,02
|
19,02
|
IPPA
|
CDI
|